中国抗体-B：截至二零二四年十二月三十一日止年度全年业绩公告;及更改所得款项用途

SinoMab BioScience Limited 3681 •(Suciraslimab, SM03)CD-22—RABLAGMP393 •SM17IL-25–SM17(EAACI)AllergySM17ADJAK1SM171Frontiers in Immunology AD1a1b1b32 •— •58.0243.1185.1(i)(Suciraslimab)BLASM17 1(ii) •141.4233.1 •73.3 •73.2 • (Suciraslimab)CD22GMPRA3-Journal of Neuroinflammation SM17SM1725 (IL–25)AD(IPF)1SM17JAK1SM17(EAACI)AllergySM17ADJAK1SM171Frontiers in ImmunologySM171bSM17AD32 1bLSLV1SM17 CGCBIO InternationalConferenceSM17SN1011EVER001SN1011)(pMN)1b/2a SM17 (Suciraslimab, SM03)RASLESSMCICD22RA3BLABLA1218GMPBLA SM17IL–25ADIPFSM17SM17FDAIND1SM17PKSM17(EAACI)AllergySM17ADJAK1SM17ADINDAD1b1b32 SN1011BTKSN1011SN10114INDSLEMSNMOSDSN1011EVER001SN1011)(pMN)1b/2a SM06CD22SM06IND (Suciraslimab, SM03) (Suciraslimab, SM03)(RA)(SLE)(SS)(MCI)CD22 RA33Suciraslimab(MTX)(top-line data)RARA3530510 393 RABLABLA1218GMPBLA SLEMCI SM17 SM17IgG4-k(alarmin)25(IL–25)IISM17IL–252(ILC2s)2T(Th2)(IL–17RB)Th2IL–4IL–5 IL–9IL–13IL-25(AD)(IPF)SM17IL–252ADIPF) SM17SM17IL–252SM17IgE1--24-(DNFB)SM17Th2Th2IL–25 SM17INDFDA1(NCT05332834)1SADMADPK(LSLV)177SM17PK(EAACI)AllergySM17SM17JAK1ADFrontiers in ImmunologySM171 INDADIND1aPKSM17PK1bSM17AD1b321bLSLV ADIPF SM17 SN1011 SN1011BTK(SLE)(MS)(NMOSD)SN1011BTK 11PKSN10114INDSLEMSNMOSDSN1011 SM06 SM06CD22SM06(Suciraslimab, SM03)SM06SM06(CMC) SM09 SM09CD20(NHL)CD20 -CGC -CGC-ycBTNKCMC (bsAb) kappa-B(RANKL)CMC LifeArcLifeArcSM17LifeArc 1952.HK)Everest Medicines II (HK)LimitedSN1011EVER001SN1011)1b/2a 19,1631,200(CNC)GMPBLA 43,15875,000 (Suciraslimab, SM03)SM06SM06 SN1011 SM09 SM18PCTPCTSM32PCTSM06SM17 PCT SinoMab 67242710254059 SM17-CGC(Suciraslimab,SM03) RASM03(Suciraslimab)BLASLEMCISLEIND2 SM171(LSLV)177SM17PKADIND1a(LSLV)AD1b321bLSLV1bSM17ADSM17PKSM17IPFIND SM06)INDPK SM06INDIND SM09FDA CGCCMC BT 43,15875,000 (RA) 1,2051,638(CAGR)3.1%20205RARA328833(CAGR)16.8%RA43.4%59.8% (AD) ADAD65.7AD81.730%AD6001543Grand View Research, Inc.AD277SM17Th2IL–25SM17AD 86078.1SM17Th2IL–25 B BBBBBB a.CD22 —CD22(Suciraslimab, SM03)SM06Bb.CD20 —CD20SM09Bc.BTK —BTKSN1011B BTBADIPF IL-25IL-17RBSM17IL-25(IL-17RB)IgG4-k T B— TTTCGC-ycT NatureCD22(Suciraslimab,SM03)MCICD22 CD22AA(Suciraslimab,SM03)SM06 SM06SM09 FDA GMP 7.63.12.4 94.8135.4(i)(Suciraslimab, SM03)BLASM17 133.2(ii)8.5 67.797.6(i)13.0(ii)6.5 9.512.8 12.6 141.4233.1 91.7(i)54.8(ii)30.6(iii)41.5(iv)130.8 419.3391.43.15%3.90%3.30%4.05%) 321.9 100%185.3%63.5%) 334.3323.645.05.0158.4 5% 1,272.8 43.6 10.0SM03SM03 (1)(2)(3)(4)SM03(Suciraslimab, SM03) 1.7828,680,00050,890,400 1. 2.SM03(Suciraslimab, SM03) 1.2948,322,0938,512,62673,181,794 111.0(MCI)(Susciralimab, SM03)SM17SM17 1. C3 622436 •662(3)63 •406(2)407(2)407(3) C1 C.2.1(i)(ii)(iii)(iv)C.2.1 GeorgeWilliam Hunter CAUTHERLEYDylan Carlo TINKER 2.1185,141,00018,161,0002.1 2.12 (www.hkexnews.hk)(www.sinomab.com) 183171712–1716 42,0261,365 (185,141)(243,111) 6–– (185,141)(243,111) 1. 15303305307 2. 18,161,000185,141,000 (i) (ii) (iii) (iv) (a) (b) (c) 3.1 161177 3.2 18319397297210284211–111791072 1234 4. (i)BTK 5. 6. 25% 7. 185,141,000243,111,0001,073,649,5591,018,115,585 185,141243,111 1,073,649,5591,018,115,585 15,955,50015,955,500 8. 9. SM03 10. 31,45530,993(i)13,523– (i)1.00%2.25% 77,918101,395 (i) 138,363152,464168,284172,343 306,647324,807 41,62434,72371,01531,865 – 112,63966,588 419,286391,395 (a)768,713,000907,555,000446,797,000409,657,000(b)(i)334,261,000323,619,000(ii)44,993,0005,000,000(c)(d)3.15%3.90%3.30%4.05%) 13. (www.hkexnews.hk)(www.sinomab.com) George William Hunter CAUTHERLEYDylan Carlo TINKER